ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
+$0.04 today
- Market cap
- $3.01B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
Volume 3.17M
Average 7.07M
ADMA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ADMA Biologics, Inc.NASDAQ: ADMA
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q2 FY2026 stock-based compensation of $6.14M rose 23.6% year over year, behind the +25.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.1% from the prior quarter. Over 3 fiscal years it compounded at +56.6% a year.
Context
- Stock-based compensation amounted to 3.9% of revenue in FY2025, up 0.7 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +23.6% toward the trailing-twelve-month pace of +25.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 20.03M USD
- Year-over-year change
- +47.1%
- 4-year CAGR
- +54.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.03M | +47.1% |
| FY2024 | 2024-12-31 | 13.62M | +120.1% |
| FY2023 | 2023-12-31 | 6.19M | +18.6% |
| FY2022 | 2022-12-31 | 5.22M | +49.5% |
| FY2021 | 2021-12-31 | 3.49M | — |
Stock-Based Compensation vs competitors
How ADMA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +25.8% is the 2nd highest of 3, against a peer median of +20.9%.
- Stock-based compensation amounts to 4.5% of revenue for ADMA, versus a peer median of 9.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $22.9M USD | +25.8% | +56.6% | 4.5% | |
| LTM Mar 2026 | $18.43M USD | +74.9% | -1.1% | 9.6% | |
| LTM Mar 2026 | $11.51M USD | -33.2% | -18.7% | 20.6% | |
| LTM Jun 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding ADMA) | — | +20.9% | -9.9% | 9.6% | |
Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.65M) | (65.9M) | (28.24M) | 197.67M | 146.93M |
| Depreciation & Amortization | 5.5M | 7.11M | 8.33M | 8.05M | 8.1M |
| Deferred Income Tax | 220.76K | 0 | 0 | (84.28M) | 11.02M |
| Stock-Based Compensation | 3.49M | 5.22M | 6.19M | 13.62M | 20.03M |
| Change in Working Capital | (51.68M) | (18.29M) | (10.12M) | (18.54M) | (139.6M) |
| Accounts Receivables | (15.34M) | 13.07M | (11.92M) | (22.58M) | (108.43M) |
| Inventory | (43.19M) | (38.56M) | (9.63M) | 2.67M | (36.23M) |
| Accounts Payables | 1.36M | 799.98K | 3.84M | 4.15M | 2.33M |
| Other Working Capital | 5.49M | 6.4M | 7.58M | (2.78M) | 2.74M |
| Other Non-Cash Items | 1.75M | 12.35M | 32.64M | 2.16M | 3.92M |
| Operating Cash Flow | (112.37M) | (59.51M) | 8.8M | 118.67M | 50.4M |
| Capital Expenditures | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (22.58M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (210K) | (349K) | (316K) |
| Investing Cash Flow | (13.51M) | (13.91M) | (4.98M) | (8.58M) | (21.89M) |
| Debt Repayment | (34K) | 51.71M | (23.6M) | (60M) | (3.18M) |
| Common Stock Issued | 121.14M | 64.65M | 0 | 7.49M | 2.98M |
| Common Stock Repurchased | 0 | 0 | (1.42M) | 0 | (31.94M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (62K) | (7.51M) | (13.97M) | (5.8M) | (11.89M) |
| Financing Cash Flow | 121.05M | 108.85M | (38.99M) | (58.3M) | (44.02M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.83M) | 35.43M | (35.17M) | 51.8M | (15.52M) |
| Free Cash Flow | (125.88M) | (73.42M) | 3.82M | 110.1M | 27.82M |
ADMA Biologics, Inc.
NASDAQ:ADMA
Intrinsic Alpha fair value
Locked
Current Price
$13.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.